Oxygen therapeutics (blood substitutes) in cardiac surgery

Current Opinion in Anaesthesiology

Volumn 16, Issue 1, 2003, Pages 21-26

  Mosa, Moheb Michael ^a   Cheng, Davy C H ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Blood substitutes; Cardiac surgery; Cell free hemoglobin; Oxygen therapeutics; Transfusion alternatives

Indexed keywords

BLOOD SUBSTITUTE; DIASPIRIN CROSSLINKED HEMOGLOBIN; FLUOROCARBON; GELENPOL; HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; HEMOGLOBIN LIPOSOME; HEMOGLOBIN RAFFIMER; HEMOSPAN; HEMOZYME; HETASTARCH; HML 109; INTERLEUKIN 6; OXYCYTE; PEBULATE; PEG HB; PERFLUOROOCTANE; PERFLUOROOCTYL BROMIDE; PERFTORAN; PHER 02; POLYMERIZED HEMOGLOBIN; RECOMBINANT HEMOGLOBIN; S 9156; S NITROSYLHEMOGLOBIN; SNO HB; UNCLASSIFIED DRUG; VTX PHP;

BLOOD SUBSTITUTION; BLOOD TRANSFUSION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENCAPSULATION; FLU LIKE SYNDROME; HEART SURGERY; HEMATURIA; HEMOGLOBINURIA; HUMAN; HYPERTENSION; JAUNDICE; OXYGEN THERAPY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0037323080     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200302000-00004     Document Type: Review

References (27)

1. Ruel MA, Rubens FD. Non-pharmacological strategies for blood conservation in cardiac surgery. Can J Anesth 2001; 48:S13-S23. • This review presents comprehensive nonpharmacological strategies aimed at reducing blood use in cardiac surgical patients.
2. Hardy JF, Pharmacological strategies for blood conservation in cardiac surgery: erythropoietin and antifibrinolytics. Can J Anesth 2002; 48:S24-S31. • This article summarizes the meta-analysis of erythropoietin and antifibrinolytics in cardiac surgery.
3. Thurer RL. Blood transfusion in cardiac surgery. Can J Anesth 2001; 48:S6-S12. • This article reviews the variability and pattern of transfusion practice in cardiac surgery, including its infectious and noninfectious risks and the impact of new technologies.
4. Silcestry SC, Smith PK, Current status of cardiac surgery in the abciximab-treated patient. Ann Thorac Surg 2000; 70:S12-S19.
5. American Red Cross. Year to date collections and distribution, www.redcross.org/news [accessed 30 April 2001].
6. Dietz NM, Joyner MJ, Warner MA. Blood substitutes: fluids, drugs or miracle solutions? Anesth Analg 1996; 82:390-405.
7. Canadian Coordinating Office for Health Technology Assessment. Issues in emerging health technologies; July 2001; issue 21.
8. Robalino BD, Mawick T, Lafont A, et al. Protection against ischemia during prolonged balloon inflation by distal coronary perfusion with use of autoperfusion catheter or fluosol. J Am Coll Cardiol 1992; 20:1378-1384.
9. Frumento RJ, Mongero L, Naka Y, Bennett-Guerrero E. Preserved gastric tonometric variables in cardiac surgical patients administered intravenous perflubron emulsion. Anesth Analg 2002; 94:809-814. • This article suggests potential preservation of postoperative gastrointestinal tract function in cardiac surgical patients with perfluorocarbons.
10. McDonagh P, Cerney K, Hokama J, et al. Perfluborn emulsion reduces inflammation during extracorporeal circulation. J Surg Res 2001; 99:7-16.
11. Noveck RJ, Sahhon EJ, Shorr JS, et al. Randomized safety studies of intravenous perflubron emulsion: II. Effects on immune function in healthy volunteers. Anesth Analg 2000; 91:812-822.
12. Leese PT, Noveck RJ, Short JS, et al. Randomized safety studies of intravenous perflubron emulsion: I. Effects on coagulation function in health volunteers. Anesth Analg 2000; 91:804-811.
13. Hill SE, Leone BJ, Faithfull S, et al. Perflubron emulsion (AF0144) augments harvesting of autologous blood: a phase II study in cardiac surgery. J Cardiothorac Vasc Anesth 2002; 16:555-560. • This multicenter study presents the feasibility of harvesting intraoperative autologous blood and the safety and efficacy of the limitations of perfluorocarbons in cardiac surgery.
14. Hill SE. Oxygen therapeutics: current concepts. Can J Anesth 2002; 48:S32-S50.
15. Savitsky JP, Doczi J, Black J, Arnold JD. A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 1978; 23:73-80.
16. Creteur J, Sibbald W, Vincent J-L. Hemoglobin solutions not just red cell substitutes. Crit Care Med 2000; 28:3025-3034.
17. Winslow RM. Blood substitutes. Adv Drug Deliv Rev 2000; 40:131-142.
18. Lamy ML, Daily EK, Brichant J-F, et al. Cardiac surgery trial collaborative group: randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. Anesthesiology 2000; 92:646-656.
19. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 1999; 282:1857-1864.
20. Pearce LB, Gawryl MS, Overview of preclinical and clinical efficacy of Biopure's HBOCs. In: Chang TMS, editor. Blood substitutes: principles, methods, products and clinical trials. New York: Karger Langer Systems; 1998. pp. 82-100.
21. Levy JH, Goodnough LT, Greilich PE, et al. Polymeralized bovine hemoglobin solution as a replacement for allogenic red cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 2002; 124:35-42. •• This prospective randomized, double-blind trial suggests Hemopure can reduce allogenic blood transfusion in 34% of postcardiac surgical patients.
22. LaMuraglia GM, O'Hara PJ, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vase Surg 2000; 31:299-308.
23. Gonzalez P, Hachney AC, Jones S, et al. A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study. J Investig Med 1997; 45:258-264.
24. Cheng DCH. Safety and efficacy of O-raffinose cross-linked human hemoglobin in cardiac surgery. Can J Anesth 2001; 48:S41-S48. • This article presents preliminary safety and efficacy data of Hemolink in a dose-response study in cardiac surgical patients.
25. Karski J, Cheng DCH, Biro GP, Carmichael FJ. The effects of Hemolink (o raffinose cross-linked human hemoglobin) on systemic oxygenation in patients undergoing CABG while on bypass [abstract]. In: 28th World Congress of the International Society of Hematology Meeting; August 2000.
26. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998; 187:199-200.
27. Johnson JL, Moore EE, Offner PJ, et al. Resuscitation with a blood substitute abrogates pathologic postinjury neutrophil cytotoxic function. J Trauma 2001; 50:449-455.